Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

NCT05163028 is registered in ClinicalTrials.gov with HUYABIO International, LLC. as lead sponsor.

NCT NCT05163028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05163028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
Lead sponsor
HUYABIO International, LLC.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 13, 2021
Completion date
December 31, 2026
Enrollment
42 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer of colon, cancer of pancreas, colorectal cancer, non small cell lung cancer, pancreatic cancer, solid tumor